Template:Mesangial proliferative glomerulonephritis: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue" |- | colspan="1" style="text-align:center; background:DarkGray" | '''M...") |
No edit summary |
||
Line 11: | Line 11: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis|Home]] | [[Mesangial proliferative glomerulonephritis|Home]] | ||
|- | |||
|- | |||
! | ! | ||
Line 23: | Line 17: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis overview|Overview]] | [[Mesangial proliferative glomerulonephritis overview|Overview]] | ||
|- | |||
|- | |||
! | ! | ||
Line 41: | Line 23: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis pathophysiology|Pathophysiology]] | [[Mesangial proliferative glomerulonephritis pathophysiology|Pathophysiology]] | ||
|- | |- | ||
! | ! | ||
Line 47: | Line 29: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis causes|Causes]] | [[Mesangial proliferative glomerulonephritis causes|Causes]] | ||
|- | |- | ||
! | ! | ||
Line 53: | Line 35: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis differential diagnosis|Differentiating Mesangial proliferative glomerulonephritis from other Diseases]] | [[Mesangial proliferative glomerulonephritis differential diagnosis|Differentiating Mesangial proliferative glomerulonephritis from other Diseases]] | ||
|- | |- | ||
! | ! | ||
Line 59: | Line 41: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis epidemiology and demographics|Epidemiology and Demographics]] | [[Mesangial proliferative glomerulonephritis epidemiology and demographics|Epidemiology and Demographics]] | ||
|- | |- | ||
! | ! | ||
Line 65: | Line 47: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis risk factors|Risk Factors]] | [[Mesangial proliferative glomerulonephritis risk factors|Risk Factors]] | ||
|- | |||
|- | |||
! | ! | ||
Line 77: | Line 53: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis natural history, complications and prognosis|Natural History, Complications and Prognosis]] | [[Mesangial proliferative glomerulonephritis natural history, complications and prognosis|Natural History, Complications and Prognosis]] | ||
|- | |- | ||
! | ! | ||
Line 83: | Line 59: | ||
! | ! | ||
Diagnosis | Diagnosis | ||
|- | |- | ||
! | ! | ||
Line 89: | Line 65: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis history and symptoms|History and Symptoms]] | [[Mesangial proliferative glomerulonephritis history and symptoms|History and Symptoms]] | ||
|- | |- | ||
! | ! | ||
Line 95: | Line 71: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis physical examination|Physical Examination]] | [[Mesangial proliferative glomerulonephritis physical examination|Physical Examination]] | ||
|- | |- | ||
! | ! | ||
Line 101: | Line 77: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis laboratory findings|Laboratory Findings]] | [[Mesangial proliferative glomerulonephritis laboratory findings|Laboratory Findings]] | ||
|- | |||
|- | |||
! | ! | ||
Line 119: | Line 83: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis CT|CT]] | [[Mesangial proliferative glomerulonephritis CT|CT]] | ||
|- | |- | ||
! | ! | ||
Line 125: | Line 89: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis MRI|MRI]] | [[Mesangial proliferative glomerulonephritis MRI|MRI]] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightSkyBlue" | |- bgcolor="LightSkyBlue" | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis | [[Mesangial proliferative glomerulonephritis ultrasound|Ultrasound]] | ||
|- | |- | ||
! | ! | ||
Line 137: | Line 101: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis other imaging findings|Other Imaging Findings]] | [[Mesangial proliferative glomerulonephritis other imaging findings|Other Imaging Findings]] | ||
|- | |- | ||
! | ! | ||
Line 143: | Line 107: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis other diagnostic studies|Other Diagnostic Studies]] | [[Mesangial proliferative glomerulonephritis other diagnostic studies|Other Diagnostic Studies]] | ||
|- | |- | ||
! | ! | ||
Line 149: | Line 113: | ||
! | ! | ||
Treatment | Treatment | ||
|- | |- | ||
! | ! | ||
Line 155: | Line 119: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis medical therapy|Medical Therapy]] | [[Mesangial proliferative glomerulonephritis medical therapy|Medical Therapy]] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis | [[Mesangial proliferative glomerulonephritis secondary prevention|Secondary Prevention]] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis | [[Mesangial proliferative glomerulonephritis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis | [[Mesangial proliferative glomerulonephritis future or investigational therapies|Future or Investigational Therapies]] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="CadetBlue" | |- bgcolor="CadetBlue" | ||
! | ! | ||
Case Studies | Case Studies | ||
|- | |- | ||
! | ! | ||
Line 197: | Line 149: | ||
! | ! | ||
[[Mesangial proliferative glomerulonephritis case study one|Case #1]] | [[Mesangial proliferative glomerulonephritis case study one|Case #1]] | ||
|- | |- | ||
! | ! | ||
Line 203: | Line 155: | ||
! | ! | ||
{{PAGENAME}} On the Web | {{PAGENAME}} On the Web | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most recent articles] | [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most recent articles] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://scholar.google.com/scholar?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=ps Most cited articles] | [http://scholar.google.com/scholar?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=ps Most cited articles] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D Review articles] | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D Review articles] | ||
|- | |- | ||
! | ! | ||
Line 227: | Line 179: | ||
! | ! | ||
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:health_continuing_education&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col3&cd=2 CME Programs] | [http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:health_continuing_education&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col3&cd=2 CME Programs] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint slides] | [http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint slides] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images] | [http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images] | ||
|- | |- | ||
! | ! | ||
Line 250: | Line 202: | ||
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} CT}}}} CT Images] | :[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} CT}}}} CT Images] | ||
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} MRI}}}} MRI] | :[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} MRI}}}} MRI] | ||
|- | |- | ||
! | ! | ||
Line 256: | Line 208: | ||
! | ! | ||
[http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials at Clinical Trials.gov] | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials at Clinical Trials.gov] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse] | [http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchType=guidance NICE Guidance] | [http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchType=guidance NICE Guidance] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}] | [http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://www.cdc.gov/search.do?queryText={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchButton.x=33&searchButton.y=6&action=search CDC on {{PAGENAME}}] | [http://www.cdc.gov/search.do?queryText={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchButton.x=33&searchButton.y=6&action=search CDC on {{PAGENAME}}] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the news] | [http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the news] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]</small> | [http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]</small> | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://maps.google.com/maps?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|map+top+hospital+Mesangial proliferative glomerulonephritis}}}}&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&ie=UTF-8&sa=N&hl=en&tab=wl Directions to Hospitals Treating Mesangial proliferative glomerulonephritis] | [http://maps.google.com/maps?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|map+top+hospital+Mesangial proliferative glomerulonephritis}}}}&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&ie=UTF-8&sa=N&hl=en&tab=wl Directions to Hospitals Treating Mesangial proliferative glomerulonephritis] | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=QWo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+risk+score+OR+risk+calculator&btnG=Search Risk calculators and risk factors for {{PAGENAME}}] | [http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=QWo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+risk+score+OR+risk+calculator&btnG=Search Risk calculators and risk factors for {{PAGENAME}}] | ||
|- | |- | ||
! | ! | ||
|} | |} |
Latest revision as of 16:59, 27 September 2012
Mesangial proliferative glomerulonephritis Microchapters |
Differentiating Mesangial proliferative glomerulonephritis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Mesangial proliferative glomerulonephritis On the Web |
American Roentgen Ray Society Images of Mesangial proliferative glomerulonephritis |
Directions to Hospitals Treating Mesangial proliferative glomerulonephritis |
Risk calculators and risk factors for Mesangial proliferative glomerulonephritis |